Report cover image

Systemic Inflammatory Response Syndrome - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 50 Pages
SKU # DEL18680127

Description

Systemic Inflammatory Response Syndrome - Pipeline Insight, 2024



DelveInsight’s, “Systemic Inflammatory Response Syndrome (SIRS) – Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Systemic Inflammatory Response Syndrome (SIRS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Systemic Inflammatory Response Syndrome (SIRS) Understanding

Systemic Inflammatory Response Syndrome (SIRS): Overview

Systemic inflammatory response syndrome (SIRS) is a heightened defense response of the body to various stressful conditions to the body. It is nonspecific and can be caused by inflammation, ischemia, infection, trauma, sepsis, or other stresses combined.

Symptoms

Clinically, symptoms of SIRS can be identified by two or more symptoms which would include hypothermia or fever, tachypnoea, tachycardia, and change in blood leucocyte count.

Diagnosis

Diagnosing Systemic Inflammatory Response Syndrome (SIRS) may be done by assessing a range of tests that may include complete blood cell count, blood cultures, sputum gram stain and culture, urinalysis and culture, liver profiles, cardiac enzymes, venous or arterial blood gases, lactate, and other tests. Even though no imaging studies exist for SIRS, they may be prescribed based on etiology of the condition.

Treatment

Presently, there is no cure available for the treatment of Systemic Inflammatory Response Syndrome (SIRS). The treatment is majorly supportive and symptomatic. The management of symptoms is done by treating the underlying etiology.

Systemic Inflammatory Response Syndrome (SIRS) Emerging Drugs Chapters

This segment of the Systemic Inflammatory Response Syndrome (SIRS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I/II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Systemic Inflammatory Response Syndrome (SIRS) Emerging Drugs
  • Exebacase: ContraFect
Exebacase is a recombinant cell wall hydrolase enzyme with strong bactericidal activity against Staph auerues, which is a major causative agent of bloodstream infections, commonly known as bacteremia. It targets the peptidoglycan wall of the Staph aureus bacteria. Some in vitro and vivo studies have also reported Exbebacase highly effective against biofilms.
  • Rezafungin acetate: Cidera Therapeutics
Rezafungin acetate is a novel molecule from the echinocandin class of antifungals. It is being developed by Cidera Therapeutics for the prevention and treatment of serious, and invasive fungal infections. It is being developed as once-weekly and high exposure therapy for the treatment of invasive candidiasis and candidemia. It is a new beta-glucan synthase inhibitor which disturbs fungal cell glucan synthesis.

Further product details are provided in the report……..

Systemic Inflammatory Response Syndrome (SIRS): Therapeutic Assessment

This segment of the report provides insights about the different Systemic Inflammatory Response Syndrome (SIRS) drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Systemic Inflammatory Response Syndrome (SIRS)
There are approx. 10+ key companies which are developing the therapies for Systemic Inflammatory Response Syndrome (SIRS). The companies which have their Systemic Inflammatory Response Syndrome (SIRS) drug candidates in the early to advanced stage, i.e. phase I and Phase III include Cidera Therapeutics and others.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like
  • Late-stage products (Phase III and Phase II/III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Systemic Inflammatory Response Syndrome (SIRS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Systemic Inflammatory Response Syndrome (SIRS): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II/II, II, I/II, I, preclinical and discovery stage. It also analyses Systemic Inflammatory Response Syndrome (SIRS) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Systemic Inflammatory Response Syndrome (SIRS) drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Systemic Inflammatory Response Syndrome (SIRS) R&D. The therapies under development are focused on novel approaches to treat/improve Systemic Inflammatory Response Syndrome (SIRS).
Systemic Inflammatory Response Syndrome (SIRS) Report Insights
  • Systemic Inflammatory Response Syndrome (SIRS) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Systemic Inflammatory Response Syndrome (SIRS) Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Systemic Inflammatory Response Syndrome (SIRS) drugs?
  • How many Systemic Inflammatory Response Syndrome (SIRS) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Systemic Inflammatory Response Syndrome (SIRS)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Systemic Inflammatory Response Syndrome (SIRS) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Systemic Inflammatory Response Syndrome (SIRS) and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Cidera Therapeutics
  • ContraFect
  • Scynexis
Key Products
  • Rezafungin acetate
  • Exebacase
  • Ibrexafungerp citrate

Table of Contents

50 Pages
Introduction
Executive Summary
Systemic Inflammatory Response Syndrome (SIRS): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Systemic Inflammatory Response Syndrome (SIRS) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Systemic Inflammatory Response Syndrome (SIRS) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Systemic Inflammatory Response Syndrome (SIRS) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage (Phase III)
Comparative Analysis
Exebacase: ContraFect
Product Description
Research and Development
Product Development Activities
Rezafungingacetate: Cidera Therapeutics
Product Description
Mid Stage (Phase II)
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Systemic Inflammatory Response Syndrome (SIRS) Key Companies
Systemic Inflammatory Response Syndrome (SIRS) Key Products
Systemic Inflammatory Response Syndrome (SIRS)- Unmet Needs
Systemic Inflammatory Response Syndrome (SIRS)- Market Drivers and Barriers
Systemic Inflammatory Response Syndrome (SIRS)- Future Perspectives and Conclusion
Systemic Inflammatory Response Syndrome (SIRS) Analyst Views
Systemic Inflammatory Response Syndrome (SIRS) Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us